Cell painting provides an open-ended, unbiased approach with which to learn what a test article does to your cell or disease model. Rather than focusing on a defined set of molecular markers, cell painting measures changes in key structural components including the nucleus, Golgi/ER, actin cytoskeleton and overall cell shape.
Phenovista offers cell painting screens in diverse cell models including human iPS-derived hepatocytes and cardiomyocytes. Phenovista has also applied this approach to 3D organoids.
With one of the largest commercial panels of cell painting-based assays available and screens initiated regularly, PhenoVista's cell painting approach is an ideal choice for all stages of drug discovery and development. Cell painting provides a platform from which follow-up studies may include target discovery & validation, lead optimization, and preclinical compound safety testing.
To join our next Cell Painting Oncology Screen, contact us by June 1st, 2021.